The Journey to INDIGO The Journey to INDIGO

Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs

Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news